Summary:

- The Global Health Coalition (GHC) has invested over $250 million in research to develop a Lassa fever vaccine.
- Lassa fever is a deadly viral hemorrhagic fever endemic to West Africa, with outbreaks occurring annually and causing significant mortality.
- The GHC's investment aims to accelerate the development and testing of Lassa fever vaccine candidates, with the goal of providing a safe and effective vaccine to protect populations at risk.